Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer

Figures & data

Figure 1. The morphology of mature DCs After stimulated with TNF-α, HPVm16E7-pulsed DCs in irregular shape showed mature characteristics of larger soma with plenty of dendritic long and small bulges on their surfaces (400 × magnification). White arrow indicates long bulge and black arrow indicates small bulge.

Table 1. Percentage of DCs expressing CD1 a, CD80, CD83, CD86, HLA-DR.

	CD1a	CD80	CD83	CD86	HLA-DR
Control	24.2 ± 3.6	33.2 ± 6.7	36.9 ± 4.3	45.5 ± 2.3	59.6 ± 4.7
TNF-α	83.5 ± 4.6^a	73.4 ± 7.4^a	78.8 ± 7.2^a	86.3 ± 5.4^a	91.2 ± 4.2^a
Ad-shSOCS1-DCs	92.8 ± 4.2^a^,^c	88.6 ± 6.2^a^,^c	93.3 ± 3.8^a^,^c	93.6 ± 3.7^a^,^b	92.6 ± 3.4^a^,^b

Immature DCs were stimulated by Ad-shSOCS1. Percent of DCs expressing CD1a, CD80, CD83, CD86 and HLA-DR were detected using flow cytometry before and after 24 h TNF-α stimulation and analyzed by SPSS one-way ANOVA analysis.

^a Significant differences compared with that of the DCs control, p < 0.001;

^b no significant differences compared with that of the TNF-α control, p > 0.05;

^c significant differences compared with that of the TNF-α control or, p < 0.05.

Figure 2. Cytotoxicity assay (A) Detected by flow cytometry, 23.6% CaSki cells expressed PDL1. (B)The cytotoxicity of effector cells at 10:1, 30:1 and 90:1 E/T ratios against CaSki cells was analyzed using CCK 8 assay. When lymphocytes incubated with MPDL3280A, DCCIKs increased the cytotoxic activity against CaSki cells with 37.9% at the E:T of 30 in relative to DCCIKs in the absence of MPDL3280A (p < 0 .01).

Figure 3. In vivo antitumor activity analysis. (A) The therapeutic effect of DCCIKs in combination with MPDL3280A against mice bearing tumors was investigated in the groups of 10 BALB/C mice received 1×10⁶ CaSki cells. The therapy was initiated with normal human IgG, DCCIKs, MPDL3280A and DCCIKs in combination with MPDL3280A on day 7. Tumor volume and time experiment was analyzed using student's t-test. *p < 0.01(DCCIKs/MPDL3280A vs DCCIKs or MPDL3280A or IgG control); <0.05 (DCCIKs vs MPDL3280A or IgG control) (B) Survival rates were analyzed using the Kaplan-Meier method (log-rank test). The experiments were repeated, producing a significant statistical difference. *p < 0.01(DCCIKs/MPDL3280A vs DCCIKs or MPDL3280A or IgG control); <0.05 (DCCIKs vs MPDL3280A or IgG control).